[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"burn-scar\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:burn-scar":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,9,0,[8,42,72,88,115,151,177,201,228],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":26,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":4},"100643102","scar-management-through-serial-casting-100643102",false,"NCT07645664","Scar Management Through Serial Casting","Inclusion Criteria:\n\n* adult burn survivors who have two scars that meet the diagnostic criteria of a HSc (erythema index greater than 300 and thickness greater than 2.034 mm) and with no more than 0.5 mm thickness difference between each other;\n* are proficient in English and\u002For French;\n* provide informed consent.\n\nExclusion Criteria:\n\n* patients who sustained electrical or cold injury;\n* formed keloid scars or have only mature scars (erythema index less than 300);\n* have a a dermatological condition that could interfere with measurement reliability (eczema, psoriasis);\n* have a cognitive\u002Fpsychiatric condition that could impaired understanding of the consent process or adherence to protocol procedures.","ALL","16 Years",{"count":18,"type":19},38,"ESTIMATED","INTERVENTIONAL",[22],"NA","Scar management remains one of the major clinical challenges for burn survivors with hypertrophic scars. Beyond their visible appearance, hypertrophic scars can significantly impair physical function, reduce life satisfaction, and affect overall quality of life. According to the results of a recently completed study, the application of serial casts appears promising for the treatment of hypertrophic scars in adults who have survived a burn injury. However, this therapeutic approach has not yet been evaluated objectively in terms of scar characteristics within the context of a study with sufficient statistical power. The present project is the first study with sufficient statistical power to objectively evaluate the beneficial effects of serial casting on the characteristics of hypertrophic scars in adult burn survivors. The objective of this study is to characterize changes in thickness, elasticity, vascularization, transepidermal water loss (TEWL), itching, and pain in hypertrophic burn scars in adults after one week of treatment with serial dressings, compared to an intra-individual control scar. Our hypothesis is that relative to baseline measures the scar thickness (primary outcome), erythema index, TEWL, itch, and pain will decrease at treatment sites compared to control sites. Conversely, elasticity will increase at the treatment sites compared to control sites. This will be a prospective, longitudinal, evaluator-blinded, randomized intra-individual controlled trial.",[25],"Burn Scar",[27,28,29],"Burns","Burn Rehabilitation","Serial Casting","NOT_YET_RECRUITING","2026-06-09",{"date":33,"type":34},"2026-06-12","ACTUAL",{"date":36,"type":19},"2026-06-01",{"date":38,"type":19},"2028-11",{"name":40,"class":41},"Centre hospitalier de l'Université de Montréal (CHUM)","OTHER",{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":15,"minAge":48,"maxAge":49,"enrollmentInfo":50,"targetDuration":4,"studyType":20,"phases":52,"briefSummary":53,"conditions":54,"keywords":55,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":71},"100180182","the-role-of-fractional-vascular-laser-therapy-in-the-management-of-burn-scars-100180182","NCT01619917","The Role of Fractional Vascular Laser Therapy in the Management of Burn Scars","Inclusion Criteria:\n\n* living in Winnipeg\n* burn scar 6-12 months old\n* Fitzpatrick skin type I-III\n* thermal burn scar on trunk or extremities\n\nExclusion Criteria:\n\n* open wound","18 Years","60 Years",{"count":51,"type":19},6,[22],"While the literature tends to support the use of laser therapy in the management of burn scars, there is a definite lack of appropriately powered, randomized controlled trials. Laser therapy can be quite expensive when compared to other treatment modalities for burn scars, and while promising, its true usefulness has yet to be conclusively demonstrated. For this reason, our assessing the effects of fractional vascular lasers on burn scars. It has been hypothesized that the fractional vascular lasers work on mature scars to decrease scar formation, and the fractional laser works on scar that is quiescent to promote remodelling. The retexturing\u002F resurfacing of the laser theoretically can decrease the visibility of the mesh pattern created by meshed split thickness skin graft).\n\nObjective:\n\nTo determine the benefit of fractional vascular laser treatment in improving burn scar height, texture, vascularity and pliability in late burn scars.",[25],[56,57,58,59,60],"burn","scar","laser","fractional","vascular","RECRUITING","2026-05-11",{"date":64,"type":34},"2026-05-14",{"date":66,"type":4},"2012-11-01",{"date":68,"type":19},"2028-07-01",{"name":70,"class":41},"University of Manitoba",1,{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":76,"acronym":4,"eligibilityCriteria":77,"healthyVolunteers":11,"sex":15,"minAge":48,"maxAge":49,"enrollmentInfo":78,"targetDuration":4,"studyType":20,"phases":79,"briefSummary":80,"conditions":81,"keywords":82,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":83,"startDateStruct":84,"completionDateStruct":85,"leadSponsor":87,"locationsCount":71},"100170131","the-role-of-pulsed-dye-laser-therapy-in-the-management-of-burn-scars-100170131","NCT01488240","The Role of Pulsed Dye Laser Therapy in the Management of Burn Scars","Inclusion Criteria:\n\n* burn scar\n* living in Winnipeg\n* scar age one to 6 months\n* Fitzpatrick I-III skin type\n\nExclusion Criteria:\n\n* open wound\n* active infection\n* previous scar treatment with steroid injection or interferon\n* established disposition towards keloid scarring",{"count":51,"type":19},[22],"The purpose of this study is to determine the effects (good or bad) of pulsed dye laser treatment in burn scar height, texture, redness and pliability in acute burn injury.",[25],[56,57,58],{"date":64,"type":34},{"date":66,"type":4},{"date":86,"type":19},"2028-06-01",{"name":70,"class":41},{"id":89,"slug":90,"hasResults":11,"nctId":91,"briefTitle":92,"officialTitle":93,"acronym":4,"eligibilityCriteria":94,"healthyVolunteers":11,"sex":15,"minAge":95,"maxAge":96,"enrollmentInfo":97,"targetDuration":4,"studyType":20,"phases":99,"briefSummary":100,"conditions":101,"keywords":102,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":107,"lastUpdatePostDateStruct":108,"startDateStruct":109,"completionDateStruct":111,"leadSponsor":113,"locationsCount":71},"100640285","scar-mobilization-improves-scars-and-quality-of-life-in-burned-children-100640285","NCT07578883","Scar Mobilization Improves Scars and Quality of Life in Burned Children.","Effects of the Scar Tissue Mobilization on Scar Thickness, Pliability and Quality of Life in Children With Upper Extremity Burns.","Inclusion Criteria:\n\n* 8-13 years\n* Stable scar and referred for scar management\n* Affected upper extremity joints (shoulder, elbow and wrist) with burned injuries\n* Partial thickness and full thickness burn.\n\nExclusion Criteria:\n\n* Pre-existing skin condition or allergies\n* Neurological disorders affecting motor function\n* Fracture with burn in upper limbs\n* Patient with only superficial burns","8 Years","13 Years",{"count":98,"type":19},15,[22],"This quasi-experimental study evaluates the effect of scar tissue mobilization on scar thickness, pliability, and quality of life in children with upper extremity burns. Conducted at Mayo Hospital Lahore, children aged 8-13 will receive treatment for 5 weeks, with outcomes analyzed using SPSS 27.",[25],[103,104,105,106],"Scar tissue mobilization","Quality of life","Scar thickness","Pliability","2026-05-05",{"date":62,"type":34},{"date":110,"type":34},"2026-04-14",{"date":112,"type":19},"2026-08-05",{"name":114,"class":41},"Riphah International University",{"id":116,"slug":117,"hasResults":11,"nctId":118,"briefTitle":119,"officialTitle":120,"acronym":4,"eligibilityCriteria":121,"healthyVolunteers":11,"sex":15,"minAge":122,"maxAge":123,"enrollmentInfo":124,"targetDuration":4,"studyType":20,"phases":126,"briefSummary":129,"conditions":130,"keywords":132,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":140,"lastUpdatePostDateStruct":141,"startDateStruct":143,"completionDateStruct":145,"leadSponsor":147,"locationsCount":150},"100578109","phase-2-post-operative-use-of-fs2-to-mitigate-scarring-in-burn-patients-100578109","NCT06807021","Post-Operative Use of FS2 to Mitigate Scarring in Burn Patients","Post-operative Topical Administration of Fibrosis Inhibiting Compound FS2 in a Double- Blind, Randomized, Vehicle-controlled Study Evaluating the Safety and Mitigation of Cutaneous Scarring in Skin Graft and Donor Sites in Burn Patients","Inclusion Criteria:\n\n1. Medically able and willing to consent\u002Fassent to study requirements\n2. Male and female burn patients\n3. 12 to 65 years of age (inclusive)\n4. Able to understand the study requirements and consent without a translator. Where applicable, participant's legally authorized representative (LAR) is willing and able to agree to the requirements and restrictions of the study, be willing to give voluntary informed consent (or assent, if capable), be able to understand and read the questionnaires, carry out all study-related procedures, and communicate effectively with the study staff.\n5. Have a BMI between 15 and 35 kg\u002Fm2 (inclusive)\n6. Have clinically acceptable results in the safety laboratory tests as deemed by the investigator\n7. Have full thickness burn injury that required partial thickness skin graft (meshed or sheet) for any location other than the face and genitalia\n8. Skin graft size is between 50 cm2 and 800 cm2 (post-meshing, if a meshed graft)\n9. If skin graft is meshed, maximum skin graft expansion ratio is 1:1.5\n10. Able to apply the IPs as instructed, whether by the participants themselves or their accompanying caregivers\n\nExclusion Criteria:\n\n1. Medically unable to consent to study requirements\n2. Treatment site(s) (skin graft site) located on the face and genitalia\n3. Treatment site(s) (skin graft site and skin donor site) that has not reached complete re-epithelization at baseline, based on the investigator's assessment\n4. Expected to be medically unstable for the duration of the study period and an additional 1-month thereafter\n5. Pregnant, or attempting to become pregnant\n6. Subjects who had taken part in an interventional clinical trial within 3 months prior to admission to this trial or who are currently participating in a clinical trial, whether an investigational drug was used or not\n7. Subjects who had any clinical evidence of severe ongoing or prolonged depression or mental illness within the last year\n8. Subjects who smoke more than 20 cigarettes a day\n9. Subjects who have a history of heavy drinking in the past month, defined as more than 14 drinks per week for men or more than 7 drinks per week for women\n10. Subjects who have a history of substance abuse within the 12 months prior to screening (including having been hospitalized for such in an in-patient or out-patient intervention)\n11. Subjects with severe inhalation injury requiring FiO2 \\>50%, renal failure requiring dialysis or hemodynamic instability requiring vasopressor therapy at the time of initiation of study treatment\n12. Subjects who have scarring from previous interventions or evidence of thermal, electrical or radiation burn scars, tattoos, birthmarks or moles within 5 cm of the treatment sites\n13. Subjects with a history of abnormal keloid scarring\n14. Subjects with additional concurrent illnesses or conditions that may have interfered with wound healing like neoplastic, immune-mediated, or primary infectious disease (e.g. carcinoma, vasculitis, connective tissue disease, immune system disorders, uncontrolled HIV infection, rheumatoid arthritis, chronic renal impairment, significant hepatic impairment, inadequately or uncontrolled congestive heart failure or diabetes mellitus) or any clinically significant medical condition or history of any condition which may impair wound healing\n15. Subjects with a skin disorder that is chronic or currently active and which the investigator considers will adversely affect the healing of acute wounds or will involve the areas to be examined in this trial (including psoriasis, dermatitis, eczema)\n16. A history of radiotherapy to the study scar area\n17. Subjects who have known sensitivity to any components of the IPs\n18. Any other diagnosis, condition, physical or geographical limitation with the participant","12 Years","65 Years",{"count":125,"type":19},70,[127,128],"PHASE2","PHASE3","The goal of this study is to see how an ingredient called kynurenic acid (which we named \"FS2\") affects scar formation in people with burn injuries that need skin graft surgery. A cream with FS2 will be used on both the area where the skin graft was placed and the area where the skin was taken (donor site). The cream will be applied after the skin has healed. This study will help us understand if FS2 is safe and effective for mitigating skin scar formation in burn patients.",[25,131],"Burn Wound",[133,134,135,136,137,138,139],"Scar","Burn","skin graft","Kynurenic acid","FS2","Skin grafted wound","Donor Wound","2026-04-28",{"date":142,"type":34},"2026-05-04",{"date":144,"type":19},"2026-05-15",{"date":146,"type":19},"2026-11-06",{"name":148,"class":149},"Birch BioMed Inc","INDUSTRY",2,{"id":152,"slug":153,"hasResults":11,"nctId":154,"briefTitle":155,"officialTitle":155,"acronym":156,"eligibilityCriteria":157,"healthyVolunteers":11,"sex":15,"minAge":158,"maxAge":159,"enrollmentInfo":160,"targetDuration":4,"studyType":20,"phases":162,"briefSummary":163,"conditions":164,"keywords":165,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":169,"lastUpdatePostDateStruct":170,"startDateStruct":172,"completionDateStruct":174,"leadSponsor":175,"locationsCount":4},"100627032","effect-of-pulsed-electromagnetic-field-on-pruritus-in-burn-scars-100627032","NCT07443358","Effect of Pulsed Electromagnetic Field on Pruritus in Burn Scars","PEM","Inclusion Criteria:\n\n* Patients aged 25-40 years.\n* Patients with second and third-degree burn scars sustained at least 3 months prior to enrollment.\n* Patients experiencing a pruritus score ≥ 5 on the Visual Analog Scale (VAS).\n* Patients who have not undergone prior PEMF therapy or other physical therapy interventions for pruritus in the past 3 months.\n\nExclusion Criteria:\n\n* Patients with cardiac pacemakers, implanted defibrillators, or other electronic medical devices.\n* Pregnant or lactating women.\n* Patients with uncontrolled systemic diseases (e.g., diabetes, hypertension) or active skin infections.\n* Patients with psychological disorders that would interfere with their ability to adhere to the treatment protocol.\n* Patients with allergic reaction to food or drugs","25 Years","40 Years",{"count":161,"type":19},40,[22],"This study will be conducted to evaluate the effectiveness of pulsed electromagnetic field therapy in pruritus in patients with burn scars.",[25],[166,167,168],"burn scar","pruritus","pulsed electromagnetic field","2026-02-25",{"date":171,"type":34},"2026-03-02",{"date":173,"type":19},"2026-03-01",{"date":36,"type":19},{"name":176,"class":41},"Cairo University",{"id":178,"slug":179,"hasResults":11,"nctId":180,"briefTitle":181,"officialTitle":182,"acronym":4,"eligibilityCriteria":183,"healthyVolunteers":11,"sex":15,"minAge":48,"maxAge":4,"enrollmentInfo":184,"targetDuration":4,"studyType":20,"phases":186,"briefSummary":188,"conditions":189,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":192,"lastUpdatePostDateStruct":193,"startDateStruct":195,"completionDateStruct":197,"leadSponsor":199,"locationsCount":71},"100609358","phase-4-remimazolam-vs-propofol-in-laser-burn-cases-100609358","NCT07213544","Remimazolam vs Propofol in Laser Burn Cases","Comparison of Remimazolam Versus Propofol for Monitored Anesthetic Care in Elective Fractional Ablative CO₂ Laser","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Undergoing both outpatient Session #1 and Session #2 of fractional ablative CO2 laser therapy\n\nExclusion Criteria:\n\n* History of previous fractional ablative laser therapy for burn scar\n* Procedure expected to last longer than 30 minutes\n* Allergy such as dextran 40 or contraindication to either of the study drugs\n* Pregnant and\u002For breastfeeding\n* Subjects who are unable to or choose not to give informed consent",{"count":185,"type":19},136,[187],"PHASE4","This randomized, single-blind, crossover study compares remimazolam and propofol for monitored anesthetic care during fractional ablative CO₂ laser therapy for burn scars. The primary aim is to assess incidence of respiratory depression, defined as a need for advanced airway maneuvers (jaw thrust\u002Fchin lift, insertion of oral or nasal airway, or bag mask ventilation), and hypopnea (respiratory rate \\\u003C 8).",[25,190,191],"Hypertrophic Scarring","Procedural Sedation","2025-11-17",{"date":194,"type":34},"2025-11-20",{"date":196,"type":34},"2025-11-12",{"date":198,"type":19},"2027-01-01",{"name":200,"class":41},"Medical University of South Carolina",{"id":202,"slug":203,"hasResults":11,"nctId":204,"briefTitle":205,"officialTitle":205,"acronym":4,"eligibilityCriteria":206,"healthyVolunteers":11,"sex":15,"minAge":48,"maxAge":207,"enrollmentInfo":208,"targetDuration":4,"studyType":20,"phases":210,"briefSummary":211,"conditions":212,"keywords":215,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":219,"lastUpdatePostDateStruct":220,"startDateStruct":222,"completionDateStruct":224,"leadSponsor":226,"locationsCount":71},"100577694","phase-3-novel-strategies-for-reducing-burn-scar-itch-100577694","NCT06801626","Novel Strategies for Reducing Burn Scar Itch","Inclusion Criteria:\n\nParticipants must meet all the inclusion criteria in order to be eligible to participate in the study.\n\n* Participant has provided informed consent in a manner approved by the IRB and is willing and able to comply with the trial procedures.\n* Adults: ≥18 to \\\u003C80 years of age.\n* Has an itchy burn scar.\n\nExclusion Criteria:\n\nParticipants meeting any of the exclusion criteria at baseline will be excluded from study participation.\n\n* Failure to obtain consent or unable to return for follow up assessments.\n* Patient is unable to follow the protocol required assessments.\n* Member of a vulnerable class (e.g., prisoners, pregnant participant, etc.).\n* Any medical condition that, in the opinion of the investigator or physician, would place the participant at increased risk for participation.\n* Concurrent participation in another interventional clinical trial (to avoid confounding factors that may influence outcomes).\n* History of prior non-compliance or the presence or history of psychiatric condition (including drug or alcohol addiction) that would, in the opinion of the investigator, make it difficult for the participant to comply with the study procedures or follow the investigators instructions.\n* Age \\\u003C 18 or ≥ 80 years.\n* Taking one of the following medications: cefuroxime, dasatinib, delavirdine, neratinib, pazopanib, risedronate, or tizanidine.\n* Has a pre-existing inflammatory or itchy skin disease.\n* Is taking an H2 antihistamine for another indication.","80 Years",{"count":209,"type":19},44,[128],"The purpose of the study is to see whether using diphenhydramine (Benadryl), famotidine (Pepcid), and cromolyn sodium will decrease burn scar itch.",[25,213,214],"Itch Scarring","Wound",[216,134,217,218],"Itch","Diphenhydramine","Famotidine","2025-09-18",{"date":221,"type":34},"2025-09-24",{"date":223,"type":34},"2025-03-01",{"date":225,"type":19},"2027-11-01",{"name":227,"class":41},"The University of Texas Medical Branch, Galveston",{"id":229,"slug":230,"hasResults":11,"nctId":231,"briefTitle":232,"officialTitle":233,"acronym":4,"eligibilityCriteria":234,"healthyVolunteers":11,"sex":15,"minAge":48,"maxAge":235,"enrollmentInfo":236,"targetDuration":4,"studyType":20,"phases":238,"briefSummary":240,"conditions":241,"keywords":245,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":250,"lastUpdatePostDateStruct":251,"startDateStruct":253,"completionDateStruct":255,"leadSponsor":257,"locationsCount":71},"100486192","phase-1-efficacy-of-preconditioned-adipose-derived-stem-cells-in-fat-grafting-100486192","NCT05610878","Efficacy of Preconditioned Adipose-Derived Stem Cells in Fat Grafting","Supplementation of Autologous Fat Grafts with Curcumin Preconditioned Adipose-Derived Stem Cells in the Treatment of Facial Contour Deformities","Inclusion criteria\n\n* Age 18-50 years (male or female)\n* Body-mass index 20-30 kg\u002Fm²\n* Suitable for liposuction as assessed by the expected cosmetic results\n* Provided signed informed consent\n\nExclusion criteria\n\n* Systemic disorders include autoimmune diseases, hemorrhagic diseases, bone marrow aplasia, sepsis, cancer, and others\n* Local disorders include acne, infections and others\n* Risk factors include smoking, uncompensated diabetes, hypertension, and allergy to the drugs used for general anesthesia\n* Microbiological contamination of either the cell culture or the transplanted tissue","50 Years",{"count":237,"type":19},24,[239],"PHASE1","The aim of this study is to evaluate the comparison of therapeutic potential of curcumin preconditioned adipose derived stem cells (ASCs) enrichment fat grafting, naïve ASCs enrichment fat grafting and conventional fat grafting to correct facial contour deformities that cause aesthetic complications in patients.",[242,243,25,244],"Romberg Disease","Craniofacial Microsomia","Post-Traumatic Scar (Disorder)",[246,247,248,249],"Facial deformities","Fat grafting","Adipose derived stem cells","Preconditioning","2024-12-30",{"date":252,"type":34},"2024-12-31",{"date":254,"type":34},"2020-11-20",{"date":256,"type":19},"2025-12",{"name":258,"class":41},"University of the Punjab"]